NEW YORK (GenomeWeb) – Horizon Discovery Group announced this week a $1.2 million master services agreement with an unnamed "major global diagnostic development company and a US biopharmaceutical company" to support the development of companion diagnostics for genetically targeted oncology therapies. In the first project covered by the agreement, Horizon will generate genetically defined cell lines and related gDNA and formalin-fixed, paraffin-embedded standards. Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.